News
QDEL
23.58
-0.65%
-0.16
Top QuidelOrtho Insiders Make Bold Move With Fresh Share Purchases
TipRanks · 18h ago
QuidelOrtho Announces Planned Retirement of Chief Financial Officer
TipRanks · 22h ago
Quidelortho CFO Joseph M. Busky Intends To Retire, Effective June 30
Benzinga · 23h ago
QuidelOrtho CFO Joseph Busky to Retire June 30, 2026
Reuters · 23h ago
Director Matthew Strobeck Acquires Common Shares of QuidelOrtho Corporation
Reuters · 23h ago
QuidelOrtho CFO Joseph M. Busky Acquires Common Shares
Reuters · 1d ago
QuidelOrtho CEO Brian J. Blaser Reports Acquisition of Common Shares
Reuters · 1d ago
QuidelOrtho (QDEL) Q3 US$733 Million Loss Reinforces Bearish Profitability Narratives
Simply Wall St · 1d ago
QuidelOrtho Is Maintained at Neutral by Citigroup
Dow Jones · 2d ago
UBS Sticks to Its Hold Rating for QuidelOrtho (QDEL)
TipRanks · 2d ago
QuidelOrtho price target lowered to $30 from $35 at UBS
TipRanks · 2d ago
A Look At QuidelOrtho (QDEL) Valuation After Earnings Update And CFO Transition News
Simply Wall St · 2d ago
Analysts Are Bullish on These Healthcare Stocks: QuidelOrtho (QDEL), Atossa Therapeutics (ATOS)
TipRanks · 2d ago
QuidelOrtho price target raised to $30 from $23 at Citi
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), QuidelOrtho (QDEL) and Allogene Therapeutics (ALLO)
TipRanks · 2d ago
QUIDELORTHO CORP <QDEL.O>: CITIGROUP RAISES TARGET PRICE TO $30 FROM $23
Reuters · 2d ago
QuidelOrtho outlines $2.7B–$2.9B 2026 revenue target as company advances R&D pipeline and margin expansion
Seeking Alpha · 2d ago
QuidelOrtho (QDEL) Q4 2025 Earnings Transcript
NASDAQ · 2d ago
QuidelOrtho ‘excited’ about new product launches in 2026
TipRanks · 2d ago
QuidelOrtho sees ‘typical’ flu season with 50M-55M annual market tests
TipRanks · 2d ago
More
Webull provides a variety of real-time QDEL stock news. You can receive the latest news about Quidel through multiple platforms. This information may help you make smarter investment decisions.
About QDEL
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.